EXTON, Pa.--(BUSINESS WIRE)--Frontage, a full service contract research organization (CRO), today announced that it has expanded its service offerings to agricultural chemical companies engaged in developing products that are covered by FIFRA (Federal Insecticide, Fungicide, and Rodenticide Act) and regulated by the United States Environmental Protection Agency (EPA). The EPA recently completed an inspection of the Frontage's Exton, Pennsylvania facility on September 3rd, 2015 with no deficiencies identified. The key services now offered to agrochemical companies include pharmacokinetic evaluations of new candidates, metabolism and mass balance studies using radiolabeled compounds, residue assessments, analytical method development/validation and stability evaluations.
"Frontage has conducted several EPA-regulated studies successfully over the last few years. There is considerable synergy between pharmaceutical and agrochemical product development; hence it was very easy for us to tap into the existing talent and processes to execute these studies. Positive inspection outcomes by regulatory agencies provide our clients with confidence that Frontage's quality systems and processes are compliant with established Good Laboratory Practice regulations," said Dr. Song Li, CEO of Frontage Laboratories. "We are pleased to be able to share with our clients that Frontage continues its expansion plans to encompass EPA-regulated studies to support the growing agrochemical industry. Frontage has recently added 10,000 square feet of new laboratory space and several state-of-the-art mass spectrometry (LC-MS/MS) and radioactivity equipment in anticipation of increasing demand from these agrochemical companies," said Dr. Song Li.
Frontage is a full service CRO assisting biopharmaceutical organizations in their research and product development efforts. Spanning from the discovery stages through late-stage clinical trials, our full service offerings include bioanalysis using more than 52 LC-MS/MS instruments, preclinical and clinical studies, analytical testing, product development support, DMPK and biometrics. Our company also provides turnkey product development, bioequivalence and analytical services to generic and consumer health pharmaceutical companies to support ANDA, and 505(b)(2) new drug application submissions.
Founded in 2002, the business has grown to state-of-the art research facilities in the US and China. Our experienced teams provide study management services for all phases of clinical research, including monitoring, data management, biostatistics and medical writing.
Frontage has enabled biopharmaceutical and generic companies of all sizes to advance hundreds of molecules through clinical development to commercial launch in global markets. For more information, visit www.frontagelab.com